Caribou Biosciences Narrows Q1 Loss, $118.6M Cash Extends Runway, Reports Positive Clinical Data
CRBU has more than doubled off its 52-week low of $0.73.
Summary
Caribou Biosciences reported first-quarter 2026 results with revenue of $2.4M and a net loss of ($25.09M), or ($0.26) per share, representing a significant narrowing of the net loss year-over-year. Crucially, the company reported $118.6M in cash and securities, which management expects to fund operations for at least 12 months. This is a material positive development, especially considering the previous 10-K (March 5, 2026) had indicated insufficient funds for a planned pivotal clinical trial. Additionally, the company announced positive clinical milestones, including an 86% overall response rate for its ANTLER phase 1 optimized cohort for Vispa-cel and a 92% ORR for CB-011 in BCMA-naive patients. Traders will monitor the company's progress in securing additional financing and further clinical trial results.
At the time of this announcement, CRBU was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.3M. The 52-week trading range was $0.73 to $3.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.